Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Concentration

<< Previous

Bullboard Posts

Next >>

Comment by Benedictuson Aug 26, 2023 9:41pm

237 Views

Post# 35607007

RE:RE:RE:Concentration

Mugs, I'm certainly not arguing the potential could be much bigger but I'm more comfortable using past performance metrics for basic assumptions. A successful p2 for $4B chronic enabled the stock to peak around $400M (give or take) so 10% of peak US I believe is a fair assumption for successful p2 acute. I'd also imagine momentum traders will exit in that zone as well due to risk/reward reversal and opportunity cost. That certainly rewarded the traders in this last go round!

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant